Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pfizer Inc. filings document the financial, governance, capital-structure, and material-event disclosures of a global biopharmaceutical company. The company's 8-K reports include quarterly operating results, financial guidance updates, Regulation FD disclosures, clinical or regulatory disclosure categories, material agreements, and other corporate events tied to its medicines, vaccines, pipeline, and commercial organization.
Pfizer's proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation, shareholder voting results, and equity-plan governance. Its capital markets filings and 8-K exhibits also disclose common stock, NYSE-listed notes, shelf registration activity, public debt offerings, note maturities, and related capital-structure terms.
Pfizer Inc. ownership filing: The Vanguard Group filed an amendment reporting 0 shares of Pfizer common stock, representing 0% of the class. The filing states that on January 12, 2026 Vanguard completed an internal realignment and now reports beneficial ownership of certain subsidiaries separately in reliance on SEC Release No. 34-39538 (January 12, 1998).
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. It lists Vanguard's address as 100 Vanguard Blvd., Malvern, PA and reiterates that no single outside person holds more than 5% of the class according to the disclosure.
Pfizer Inc. reported that Chairman and CEO Albert Bourla acquired 1,630 phantom stock units linked to Pfizer common stock. The units were granted at a reference price of $26.58 per unit under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan.
Each unit tracks one share of common stock but is settled in cash after his separation from service rather than in actual shares. Following this grant, Bourla holds a total of 759,400 phantom stock units, providing cash-based exposure to Pfizer’s share value as part of his long-term compensation.
Pfizer Inc. is asking shareholders at its virtual April 23, 2026 annual meeting to elect 12 directors, ratify KPMG as auditor, approve the amended 2019 Stock Plan, hold an advisory vote on executive pay and consider a shareholder proposal for an independent chair.
The proxy highlights 2025 results: total revenue of $62.6 billion versus $63.6 billion with a 2% operational decline, but 6% operational growth excluding COVID-19 products. Pfizer advanced a 102-project R&D pipeline and completed strategic deals including the Metsera acquisition and licensing agreements with 3SBio and YaoPharma.
Cost realignment is expected to deliver about $5.7 billion in net savings by 2026, plus roughly $1.5 billion from manufacturing optimization by 2027. In 2025 the company returned $9.8 billion in cash dividends, invested $10.4 billion in internal R&D and about $8.8 billion in business development, while maintaining a long dividend record and emphasizing board independence and risk oversight.
Pfizer Inc. senior vice president and controller Jennifer B. Damico reported equity compensation activity and related tax withholding. On March 3, she received grants of Pfizer common stock totaling 21,719 shares in the form of restricted stock units, which are subject to vesting requirements, and 22,638 stock appreciation rights that will be settled in common shares on the fifth anniversary of the grant date.
On March 4, 826 shares of common stock were withheld to cover tax obligations when restricted stock units (and related dividend equivalents) vested. After these transactions, she directly held 32,934 Pfizer common shares.
Pfizer Inc. reported that Chairman and CEO Albert Bourla received a grant of 708,666 stock appreciation rights on March 3, 2026. These rights were acquired as a grant or award, not through open-market purchases.
According to the disclosure, the stock appreciation rights are subject to vesting conditions and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this transaction, Bourla held a total of 708,666 stock appreciation rights directly.
BOSHOFF CHRISTOFFEL reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. reported that President of R&D Christoffel Boshoff received a grant of 259,844 stock appreciation rights on March 3, 2026. These derivative awards carry no purchase price and are part of his equity-based compensation.
The stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, aligning the executive’s potential reward with long-term company performance.
Pfizer Inc. reported that Chief Financial Officer and EVP David M. Denton received a grant of 216,537 Stock Appreciation Rights on March 3, 2026. These awards were acquired at a stated price of $0.00 per right, reflecting an equity-based compensation grant rather than an open-market purchase.
The footnote explains that the stock appreciation rights are subject to vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. Following this grant, Denton’s reported direct derivative holdings in these rights total 216,537.
Pfizer Inc. Executive Vice President Douglas M. Lankler reported an acquisition of 194,883 stock appreciation rights on March 3, 2026. These derivative awards carry no exercise price and are scheduled to be settled in Pfizer common stock on the fifth anniversary of the grant date, subject to vesting conditions.
MALIK AAMIR reported acquisition or exercise transactions in this Form 4 filing.
Pfizer executive vice president Aamir Malik received a grant of 194,883 stock appreciation rights on March 3, 2026. These derivative awards were granted at no cost and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant, subject to vesting requirements.